Sullivan Bruyette Speros & Blaney LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.9% in the second quarter, according to its most recent filing with the SEC. The fund owned 6,094 shares of the biopharmaceutical company’s stock after selling 453 shares during the period. Sullivan Bruyette Speros & Blaney LLC’s holdings in Gilead Sciences were worth $431,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently made changes to their positions in GILD. ING Groep NV raised its position in Gilead Sciences by 21.5% during the 1st quarter. ING Groep NV now owns 452,782 shares of the biopharmaceutical company’s stock worth $30,753,000 after purchasing an additional 80,061 shares during the last quarter. State Treasurer State of Michigan raised its position in Gilead Sciences by 4.7% during the 1st quarter. State Treasurer State of Michigan now owns 3,175,801 shares of the biopharmaceutical company’s stock worth $215,700,000 after purchasing an additional 143,500 shares during the last quarter. Welch Group LLC raised its position in Gilead Sciences by 9.7% during the 1st quarter. Welch Group LLC now owns 2,857 shares of the biopharmaceutical company’s stock worth $194,000 after purchasing an additional 252 shares during the last quarter. LSV Asset Management raised its position in Gilead Sciences by 1.7% during the 1st quarter. LSV Asset Management now owns 2,230,644 shares of the biopharmaceutical company’s stock worth $151,505,000 after purchasing an additional 36,257 shares during the last quarter. Finally, Nwam LLC raised its position in Gilead Sciences by 9.6% during the 1st quarter. Nwam LLC now owns 12,404 shares of the biopharmaceutical company’s stock worth $842,000 after purchasing an additional 1,084 shares during the last quarter. Institutional investors own 74.28% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $73.46 on Friday. The firm has a market capitalization of $96.47 billion, a P/E ratio of 7.70, a P/E/G ratio of -1.24 and a beta of 1.13. The company has a debt-to-equity ratio of 1.18, a quick ratio of 4.74 and a current ratio of 4.86.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. The company had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. Gilead Sciences’s revenue was down 13.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.75 EPS. equities analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.83%. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.69%.

In related news, CFO Robin L. Washington sold 51,820 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the sale, the chief financial officer now owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the sale, the executive vice president now directly owns 77,363 shares in the company, valued at approximately $5,788,299.66. The disclosure for this sale can be found here. Insiders sold a total of 446,819 shares of company stock worth $36,269,486 in the last ninety days. 1.30% of the stock is currently owned by insiders.

GILD has been the subject of several analyst reports. Jefferies Group LLC reaffirmed a “hold” rating and set a $80.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 11th. Morgan Stanley reaffirmed an “equal weight” rating on shares of Gilead Sciences in a research report on Tuesday, July 11th. Robert W. Baird reaffirmed an “outperform” rating and set a $87.00 target price on shares of Gilead Sciences in a research report on Thursday, July 13th. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 target price for the company in a research report on Monday, July 17th. Finally, BMO Capital Markets reaffirmed a “hold” rating and set a $72.00 target price on shares of Gilead Sciences in a research report on Friday, July 21st. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $85.68.

ILLEGAL ACTIVITY WARNING: This piece was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/sullivan-bruyette-speros-blaney-llc-reduces-stake-in-gilead-sciences-inc-gild/1677314.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.